MannKind (MNKD) closed its books for the fourth quarter 2019 and enters 2020 with increased probability for Afrezza to easing the burden of glucose management for diabetics.
In a post-analysis, it was demonstrated Afrezza caused fewer hypoglycemic events compared to another rapid-acting insulin analog. This has good long-term implications for Afrezza's prospects but will require additional studies if Afrezza is to convince the cautious medical establishment and tight fisted insurance companies to consider diabetic’s long-term health.
Before discussing the study I will review some numbers for investors to chew on. During the fo